Very high-magnification micrograph of Ewing sarcoma in the lung. Credit: Nephron.

Gradalis has started a Phase lll clinical trial of Vigil in combination with irinotecan and temozolomide for the treatment of patients with Ewing’s sarcoma (EWS).

The multicentre, randomised, open-label trial intends to analyse the study drug combination as a second-line regimen for EWS, a rare form of pediatric cancer that originates in bone or soft tissue.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Caused by genetic mutation, EWS is currently estimated to affect around 1,000 individuals across the globe every year.

The Phase lll trial is expected to enrol around 140 patients with metastatic Ewing’s sarcoma family of tumours (ESFT) refractory/intolerant or recurrent to one prior line of chemotherapy.

The enrolled patients will be randomised in 1:1 ratio to receive daily oral dose of temozolomide 100mg/m² and daily oral dose of irinotecan 50mg/m² for five days.

They will also receive Vigil 1.0 x 10e6 cells/injection cells/injection, intradermally on day 15.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“For patients affected by Ewing’s sarcoma, our most recent trial has shown positive results with minimal side effects.”

The trial’s primary endpoint is progression free survival (PFS), while its secondary endpoints include overall survival (OS) and radiological tumour assessment.

Gradalis chief medical officer John Nemunaitis said: “For patients affected by Ewing’s sarcoma, our most recent trial has shown positive results with minimal side effects.

“We believe Gradalis’ approach of exploiting the patient’s existing, highly adapted immune system by presenting the entire neoantigen matrix and induced T-cell responses against their cancer has great promise.”

In addition, Gradalis is conducting a number of other clinical studies for Vigil for the treatment of various types of cancer.

Vigil is currently being evaluated as a cellular immunotherapy technology that combines genetic engineering with immuno-oncology.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact